NextCure to Present at 11th Annual SVB Leerink Global Healthcare Conference

2 years ago

BELTSVILLE, Md., Feb. 08, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and…

Beyond Air® Announces Participation at Upcoming Investor Conferences in March 2022

2 years ago

GARDEN CITY, N.Y., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical…

Soleno Therapeutics to Participate in the BIO CEO & Investor Conference

2 years ago

REDWOOD CITY, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing…

Salarius Pharmaceuticals to Participate in the 2022 BIO CEO & Investor Conference

2 years ago

HOUSTON, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines…

Palisade Bio (Nasdaq: PALI) to Announce Adhesions Clinical Data at SAGES 2022 Annual Meeting

2 years ago

Incidence and Severity of Post-Surgical Intraabdominal Adhesions following Bowel Resection Surgery and Treatment with Enteral Protease Inhibitor LB1148CARLSBAD, Calif., Feb.…

Frontier Medicines Announces Renowned Physician Scientist Piro Lito, M.D., Ph.D., Joins Scientific Advisory Board

2 years ago

SOUTH SAN FRANCISCO, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock…

GelStat Announces $5 Million Public Offering Under Regulation A+

2 years ago

GelStat Corporation Has Been Qualified by the SEC for a Regulation A+ Public OfferingSTUART, Fla., Feb. 08, 2022 (GLOBE NEWSWIRE)…

Werewolf Therapeutics to Present at the SVB Leerink Global Healthcare Conference

2 years ago

CAMBRIDGE, Mass., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical…

Akero Therapeutics Completes Enrollment of Phase 2b HARMONY Study in Pre-Cirrhotic NASH Patients

2 years ago

SOUTH SAN FRANCISCO, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for…

Gain Therapeutics Presents Preclinical Data on its Structurally Targeted Allosteric Regulators in GBA1 Gaucher Disease at the WORLDSymposium 2022

2 years ago

Study results demonstrate GBA1-targeted allosteric regulators increase GCase protein levels, reduce the production of inflammatory cytokines, and improve key lysosomal…